ANDHealth Co-Founder and Managing Director Bronwyn Le Grice pioneered the unique non-profit industry-led model supporting Australian digital health companies navigate the commercialisation path to institutional investment and international market entry.
Since inception, ANDHealth has been delivering programs designed specifically to address unique commercialisation challenges faced by digital health companies. Bronwyn’s inspiring leadership and communication skills, with an investment perspective have led the innovation path to growth and success for 10 companies in ANDHealth programs.
Bronwyn’s executive experience in the health technology sector has spanned venture capital, transaction management, capital raising, corporate development, investor relations and industry advocacy.
In her prior role as Investment Director with healthcare VC, BioScience Managers, Bronwyn was responsible for managing significant transactions resulting in over A$65m of private and public equity raisings.
After completing the $35m Adherium IPO on the ASX, Bronwyn founded ANDHealth, Australia’s only dedicated digital health accelerator.
Reflecting her role in the healthcare industry and the impact made by ANDHealth, Bronwyn was recently recognised as BioMelbourne Network’s Most Valuable Women in Leadership 2020. Under Bronwyn’s leadership and delivery by the ANDHealth team, companies in the accelerator program have raised over $28 million in capital, created more than 165 jobs and have treated over 70,000 patients since 2017.
-
Stroke care advances in translated research
New nurse-led protocols for stroke patients, based on ACU research, led by the Nursing Research Institute, have resulted in changes to policy, guidelines and clinical practice in Europe and Australia. The protocols were developed through the Quality in Acute Stroke Care (QASC) Trial (published in the Lancet, 2011) to manage fever, hyperglycaemia and swallowing (FeSS) post-stroke.
-
Nurse recognised for reducing hospital waste
A nurse who started a charity from a granny flat in her parent’s backyard to reduce hospital waste has taken out one of the Australian nursing profession’s most prestigious honours.
-
Nuclear medicine funding a win for men with prostate cancer
Australian men with higher risk prostate cancer now have access to a nuclear medicine scan to help detect and treat metastatic disease, after it was listed on the Medical Benefits Schedule (MBS) from 1st July 2022.
In 2021 over 18,000 Australian men were diagnosed with prostate cancer, resulting in over 3,000 lives being lost – and making prostate cancer Australia’s second most common cause of cancer death in men.
Australian Health Journal spoke with AANMS President Associate Professor Sze Ting Lee and Dr Geoff Schembri on the MBS listing and the efforts to get it listed.
